Logo image of TBI

TRUEBLUE INC (TBI) Stock Fundamental Analysis

USA - NYSE:TBI - US89785X1019 - Common Stock

5.71 USD
+0.04 (+0.71%)
Last: 10/22/2025, 8:04:35 PM
5.71 USD
0 (0%)
After Hours: 10/22/2025, 8:04:35 PM
Fundamental Rating

3

Overall TBI gets a fundamental rating of 3 out of 10. We evaluated TBI against 86 industry peers in the Professional Services industry. The financial health of TBI is average, but there are quite some concerns on its profitability. TBI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBI has reported negative net income.
In the past year TBI has reported a negative cash flow from operations.
In multiple years TBI reported negative net income over the last 5 years.
TBI had a positive operating cash flow in 4 of the past 5 years.
TBI Yearly Net Income VS EBIT VS OCF VS FCFTBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

TBI has a worse Return On Assets (-5.03%) than 69.77% of its industry peers.
Looking at the Return On Equity, with a value of -11.09%, TBI is doing worse than 69.77% of the companies in the same industry.
Industry RankSector Rank
ROA -5.03%
ROE -11.09%
ROIC N/A
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
TBI Yearly ROA, ROE, ROICTBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Gross Margin of TBI (24.92%) is worse than 62.79% of its industry peers.
In the last couple of years the Gross Margin of TBI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TBI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
TBI Yearly Profit, Operating, Gross MarginsTBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

5

2. Health

2.1 Basic Checks

TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBI has been reduced compared to 1 year ago.
TBI has less shares outstanding than it did 5 years ago.
TBI has a worse debt/assets ratio than last year.
TBI Yearly Shares OutstandingTBI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
TBI Yearly Total Debt VS Total AssetsTBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

TBI has an Altman-Z score of 3.31. This indicates that TBI is financially healthy and has little risk of bankruptcy at the moment.
TBI has a better Altman-Z score (3.31) than 63.95% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that TBI is not too dependend on debt financing.
TBI's Debt to Equity ratio of 0.18 is fine compared to the rest of the industry. TBI outperforms 63.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z 3.31
ROIC/WACCN/A
WACC8.9%
TBI Yearly LT Debt VS Equity VS FCFTBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.94 indicates that TBI should not have too much problems paying its short term obligations.
TBI has a better Current ratio (1.94) than 70.93% of its industry peers.
A Quick Ratio of 1.94 indicates that TBI should not have too much problems paying its short term obligations.
TBI's Quick ratio of 1.94 is fine compared to the rest of the industry. TBI outperforms 70.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.94
TBI Yearly Current Assets VS Current LiabilitesTBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TBI have decreased strongly by -650.00% in the last year.
TBI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.01%.
TBI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.93% yearly.
EPS 1Y (TTM)-650%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)-13.01%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%0.02%

3.2 Future

Based on estimates for the next years, TBI will show a very strong growth in Earnings Per Share. The EPS will grow by 67.57% on average per year.
Based on estimates for the next years, TBI will show a small growth in Revenue. The Revenue will grow by 3.69% on average per year.
EPS Next Y-14.47%
EPS Next 2Y67.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.26%
Revenue Next 2Y3.69%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TBI Yearly Revenue VS EstimatesTBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B 2.5B
TBI Yearly EPS VS EstimatesTBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TBI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 15.70, which indicates a correct valuation of TBI.
Based on the Price/Forward Earnings ratio, TBI is valued a bit cheaper than the industry average as 66.28% of the companies are valued more expensively.
TBI is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 15.7
TBI Price Earnings VS Forward Price EarningsTBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBI Per share dataTBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

A more expensive valuation may be justified as TBI's earnings are expected to grow with 67.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.57%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRUEBLUE INC

NYSE:TBI (10/22/2025, 8:04:35 PM)

After market: 5.71 0 (0%)

5.71

+0.04 (+0.71%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners94.77%
Inst Owner Change0.05%
Ins Owners5.17%
Ins Owner Change-0.17%
Market Cap170.73M
Revenue(TTM)1.53B
Net Income(TTM)-33848000
Analysts80
Price Target8.84 (54.82%)
Short Float %3.6%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.09%
Min EPS beat(2)-24.74%
Max EPS beat(2)28.92%
EPS beat(4)3
Avg EPS beat(4)30.43%
Min EPS beat(4)-24.74%
Max EPS beat(4)87.81%
EPS beat(8)5
Avg EPS beat(8)32.46%
EPS beat(12)7
Avg EPS beat(12)24.26%
EPS beat(16)10
Avg EPS beat(16)26.45%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)1.19%
Revenue beat(4)1
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)1.19%
Revenue beat(8)2
Avg Revenue beat(8)-1.29%
Revenue beat(12)2
Avg Revenue beat(12)-1.77%
Revenue beat(16)5
Avg Revenue beat(16)-0.89%
PT rev (1m)0%
PT rev (3m)4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-571.43%
EPS NY rev (1m)-11.48%
EPS NY rev (3m)-29.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.7
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.36
Fwd EY6.37%
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS51.33
BVpS10.21
TBVpS8.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.03%
ROE -11.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.92%
FCFM N/A
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
F-Score3
Asset Turnover2.28
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.18%
Cap/Sales 1.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.94
Altman-Z 3.31
F-Score3
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)102.48%
Cap/Depr(5y)103.83%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-650%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y-14.47%
EPS Next 2Y67.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.01%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%0.02%
Revenue Next Year1.26%
Revenue Next 2Y3.69%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year112.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-197.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.55%
OCF growth 3YN/A
OCF growth 5YN/A